...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychopharmacology >Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study.
【24h】

Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study.

机译：米氮平治疗广泛性焦虑症：固定剂量，开放标签研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score 7. At 12 weeks, response was achieved by 79.5% of the patients (n 35) and remission by 36.4% of patients (n 16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.
机译：我们调查了米氮平在广泛性焦虑症（GAD）中的疗效。接受固定剂量的米氮平（30mg）公开治疗四十四名GAD成人门诊患者，持续12周。主要结局指标是汉密尔顿焦虑量表（HAM-A）的总得分相对于基线的变化。在终点对临床总体改善印象（CGI-I）进行了评估。 HAM-A总分降低50％或以上且终点的CGI-I得分降低1或2的患者被视为对治疗有反应;缓解定义为HAM-A评分7。在12周时，有79.5％的患者获得了缓解（n = 35），有36.4％的患者获得了缓解（n 16）。这项研究支持米氮平是一种有效且耐受良好的GAD治疗方案。必须考虑本研究的局限性，需要进一步的安慰剂对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号